The FDA clearances expand the company’s portfolio of peripheral nerve stimulation (PNS) solutions for chronic pain management. Durham, North Carolina-based Bioventus said they mark an important step forward and a significant growth opportunity in the PNS market.

TalisMann and StimTrial add to a comprehensive portfolio that enables physicians to treat a broader spectrum of patients. It also reinforces the company’s commitment to delivering non-opioid, minimally invasive therapies for addressing real-world clinical needs.

Bioventus designed TalisMann to combine patented electric field conduction technology with an integrated pulse generator. It aims to potentially reach deeper, larger nerves to provide long-term relief from chronic nerve pain for patients. The company says its increase in power could allow for easier lead placement and potentially broaden addressable nerves.